Fewer than a tenth of patients that would benefit from weight-loss injections including Wegovy can access them, states the World Health Organization as it issues its initial advice on the therapies.
Given more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable availability to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The new guidelines recognises that excess weight is a chronic disease that can be treated with thorough and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are major barriers to universal access to the injections that can help people shift considerable body mass, explains the body.
Weight-Loss Drug Supply Crisis
Even under the current most favorable case, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, per the health organization.
The guideline urges governments and firms to widen access, by approaches such as licensing agreements.
The intellectual property rights on the active ingredient – the main component of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Injections Work
The injections mimick a body's own hormone to reduce digestion speed, curb appetite and boost the sense of being full so users reduce food intake.
Individuals commonly start to lose weight in the initial weeks of starting on the weekly injections.
Evidence points to users may put most of the weight back on a year later of halting the medication, as their usual appetite come back.
To be carrying excess weight elevates your chance for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects individuals in all nations and was responsible for millions of fatalities worldwide in 2024, as per the WHO.
